ArticleParasites, hosts and diseases2026
The therapeutic potential of green synthesized zinc oxide nanoparticles in murine schistosomiasis.
Article in Parasites, hosts and diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Schistosomiasis remains a major neglected tropical disease, affecting approximately 600 million individuals worldwide and accounting for nearly 500,000 deaths annually. The principal causative species-Schistosoma haematobium, S. mansoni, and S. japonicum-drive significant morbidity through hepatomegaly, splenomegaly, and progressive hepatic fibrosis. Praziquantel (PZQ) remains the cornerstone of treatment; however, its limited efficacy against immature worms and eggs, combined with concerns over emerging drug resistance, underscores the urgent need for novel therapeutic alternatives. This study investigated the anti-schistosomal potential of green-synthesized zinc oxide (ZnO) nanoparticles (NPs) in a murine model of S. mansoni infection, benchmarked against PZQ. ZnO NPs were fabricated using ginger extract via an eco-friendly green synthesis approach. Fifty male BALB/c mice were randomly assigned to five groups (n=10): normal control, infected untreated control, infected treated with PZQ alone, infected treated with ZnO NPs alone, and infected treated with a PZQ-ZnO NP combination. Parasitological, histopathological, and fibrosis assessments were subsequently performed. All treatment groups demonstrated significant reductions in worm burden and tissue egg counts relative to infected untreated controls. Histopathological examination of untreated infected mice revealed extensive chronic granulomatous inflammation, concentric perioval fibrosis, fibroblast proliferation, hepatocellular necrosis, hydropic degeneration, marked collagen deposition, and portal-to-portal fibrous bridging. Treated groups, by contrast, exhibited marked hepatic improvement characterized by reduced granuloma size, diminished fibrosis, and decreased collagen deposition. Collectively, these findings indicate that green-synthesized ZnO NPs possess promising anti-schistosomal and antifibrotic properties, warranting further investigation as a potential adjunct or alternative therapeutic strategy for schistosomiasis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.